In triple-negative breast cancer (TNBC), CD109 expression is increased in cancer stem cells from TNBC patients as compared to non-TNBC samples, and is linked to chemotherapeutic resistance, increased distant metastasis, and poorer disease-specific survival (87). This evidence concerns the gene CD109 and cancer.